证券代码：688613 证券简称：奥精医疗 公告编号：2026-005 奥精医疗科技股份有限公司2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以奥精医疗科技 股份有限公司（以下简称"公司"）2025年年度的定期报告为准，提请投资者注意投资风险。 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填制，但未经审计，最终结果以公司2025年年度报告为准。 二、经营业绩和财务状况情况说明 （一）报告期内公司的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况及财务状况 2025年公司实现营业总收入22,350.56万元，同比增长8.48%；实现归属于母公司所有者的净利润 1,315.06万元，同比增长203.86%；报告期末公司总资产为156,445.08万元，较期初增长1.64%，实现归 属于母公司所有者的扣除非经常性损益的净利润-91.50万元，较上年同期增长96.77%。 报 ...

影响经营业绩的主要因素：骨科人工骨集采为公司提供了临床使用继续上量、进一步扩大市场份额的机 会。以此为契机，公司同步强化了生产保障体系，确保能稳定满足集采带来的增量需求。市场营销策略 方面，公司持续深化区域市场战略，通过精细化管理和精准营销策略，不断拓宽销售网络。公司全年营 业收入呈现稳健增长态势，进一步巩固了公司在细分市场的领先地位。 奥精医疗(688613.SH)披露2025年度业绩快报，2025年公司实现营业总收入2.24亿元，同比增长8.48%;实 现归属于母公司所有者的净利润1315.06万元，同比扭亏为盈。 ...

Core Viewpoint - The performance forecast of Aojing Medical indicates a significant turnaround, with expected revenue of approximately 224 million yuan and a net profit of about 13.53 million yuan, marking a substantial increase and a return to profitability after a challenging period in the industry [1][3] Group 1: Financial Performance - Aojing Medical anticipates a revenue increase of approximately 8.48% year-on-year, reaching around 224 million yuan [1] - The company expects a net profit of approximately 13.53 million yuan, a significant increase of about 26.19 million yuan compared to the previous year, indicating a successful turnaround [1] Group 2: Market Dynamics - The implementation of centralized procurement policies for orthopedic artificial bones has been a key driver for the company's performance, leading to a "V-shaped reversal" in results [1] - The expansion of the procurement scope has transformed the pricing structure in the industry, providing Aojing Medical with opportunities for increased clinical usage and market share [1] Group 3: Operational Strategy - Aojing Medical has strengthened its production assurance system and optimized processes to meet the increased market demand resulting from centralized procurement [2] - The company has shifted its marketing strategy towards a more refined regional approach, enhancing academic promotion and channel management to solidify its leading position in the regenerative medical materials market [2] Group 4: Industry Implications - The performance changes of Aojing Medical reflect a broader trend in the medical device industry, where companies are adapting to the normalization of centralized procurement by shifting from high-margin pricing models to scale production and cost control [2] - Companies that can quickly adapt to new market rules and leverage product quality and capacity are likely to emerge successfully from industry restructuring [2]

Core Viewpoint - Aojing Medical (688613.SH) forecasts a net profit attributable to shareholders of approximately 13.53 million yuan for the year 2025, representing an increase of about 26.19 million yuan compared to the previous year, indicating a turnaround from loss to profit [1] Group 1: Performance Forecast - The company expects to achieve a net profit of approximately 13.53 million yuan in 2025 [1] - This represents an increase of about 26.19 million yuan compared to the same period last year [1] - The anticipated performance marks a significant turnaround from previous losses [1] Group 2: Reasons for Performance Change - The main reason for the performance change is the increase in clinical usage of orthopedic artificial bone due to centralized procurement, which provides opportunities for continued market share expansion [1] - The company has strengthened its production assurance system to meet the increased demand resulting from centralized procurement [1] Group 3: Marketing and Sales Strategy - The company continues to deepen its regional market strategy through refined management and targeted marketing strategies [1] - There is a steady growth trend in annual operating revenue, further consolidating the company's leading position in the niche market [1]

Core Viewpoint - The passing of Mr. Cui Fuzhai, a founder and actual controller of AoJing Medical, is a significant event for the company, but it is not expected to impact the company's management or operations due to the stability of its core technical team and ongoing business activities [2][3]. Company Overview - AoJing Medical, established in 2004, focuses on the research, production, and sales of medical devices for tissue regeneration and repair [3]. - The company is recognized for developing a biomimetic bone material that closely resembles natural human bone tissue, achieving clinical transformation and industrialization [3]. - AoJing Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in May 2021 [3]. Leadership and Contributions - Mr. Cui Fuzhai, who passed away at the age of 80, was a prominent figure in the field of biomaterials and made significant contributions to the development of the industry in China [2][4]. - He held various academic and managerial positions, including serving as the company's general manager from 2004 to 2012 and as chief scientist since June 2011 [4]. Financial Performance - In 2024, AoJing Medical reported a revenue of 206 million yuan, a year-on-year decrease of 9.03%, and a net loss attributable to shareholders of 12.66 million yuan [6]. - The decline in revenue is attributed to the nationwide implementation of centralized procurement for orthopedic artificial bones, leading to a decrease in unit prices and increased costs due to higher sales volumes [6]. - Additional factors contributing to the loss include increased market activity expenses, costs associated with the acquisition of HumanTech Dental, and extended credit terms for certain distributors [6].